Please wait while the formulary information is being retrieved.
Drug overview for TRIMIPRAMINE MALEATE (trimipramine maleate):
Generic name: TRIMIPRAMINE MALEATE (trye-MI-pra-meen)
Drug class: Antidepressants
Therapeutic class: Central Nervous System Agents
Trimipramine maleate is a dibenzazepine-derivative tricyclic antidepressant.
Trimipramine maleate shares the pharmacologic actions of the other tricyclic antidepressants and is used primarily in the treatment of endogenous depression. Studies comparing trimipramine with amitriptyline or imipramine have not demonstrated superiority of trimipramine over these other tricyclic antidepressants. In one randomized double-blind study in children 5-14 years of age, trimipramine maleate was no more effective than placebo in the treatment of enuresis+.
Generic name: TRIMIPRAMINE MALEATE (trye-MI-pra-meen)
Drug class: Antidepressants
Therapeutic class: Central Nervous System Agents
Trimipramine maleate is a dibenzazepine-derivative tricyclic antidepressant.
Trimipramine maleate shares the pharmacologic actions of the other tricyclic antidepressants and is used primarily in the treatment of endogenous depression. Studies comparing trimipramine with amitriptyline or imipramine have not demonstrated superiority of trimipramine over these other tricyclic antidepressants. In one randomized double-blind study in children 5-14 years of age, trimipramine maleate was no more effective than placebo in the treatment of enuresis+.
DRUG IMAGES
TRIMIPRAMINE MALEATE 25 MG CAP
TRIMIPRAMINE MALEATE 50 MG CAP
TRIMIPRAMINE MALEATE 100 MG CP
The following indications for TRIMIPRAMINE MALEATE (trimipramine maleate) have been approved by the FDA:
Indications:
Depression
Professional Synonyms:
Depressed mood
Depressive disorder
Depressive reaction
Depressive syndrome
Mental depression
Indications:
Depression
Professional Synonyms:
Depressed mood
Depressive disorder
Depressive reaction
Depressive syndrome
Mental depression
The following dosing information is available for TRIMIPRAMINE MALEATE (trimipramine maleate):
Dosage of trimipramine maleate is expressed in terms of trimipramine. There is a wide range of dosage requirements, and dosage must be carefully individualized. Initial dosages should be low and generally range from 75-100 mg daily.
Dosage may be gradually adjusted to the level that produces maximal therapeutic effect with minimal toxicity and may range up to 300 mg daily. Hospitalized patients under close supervision may generally be given higher dosages than outpatients, and the manufacturer states that dosages greater than 200 mg daily are not recommended for outpatients. Geriatric and adolescent patients should usually be given lower than average dosages.
The manufacturer states that therapy should be initiated with 50 mg daily in these patients and the optimal dosage rarely exceeds 100 mg daily. Maximum antidepressant effects may not occur for 2 or more weeks after therapy is begun.
After symptoms are controlled, dosage should be gradually reduced to the lowest level which will maintain relief of symptoms. If maintenance therapy is necessary, the manufacturer recommends 50-150 mg daily, preferably administered as a single daily dose at bedtime. Maintenance therapy should be continued for at least 3 months to prevent relapse.
Patients should be monitored for possible worsening of depression, suicidality, or unusual changes in behavior, especially at the beginning of therapy or during periods of dosage adjustment. (See Cautions: Precautions and Contraindications, in the Tricyclic Antidepressants General Statement 28:16.04.28.)
Dosage may be gradually adjusted to the level that produces maximal therapeutic effect with minimal toxicity and may range up to 300 mg daily. Hospitalized patients under close supervision may generally be given higher dosages than outpatients, and the manufacturer states that dosages greater than 200 mg daily are not recommended for outpatients. Geriatric and adolescent patients should usually be given lower than average dosages.
The manufacturer states that therapy should be initiated with 50 mg daily in these patients and the optimal dosage rarely exceeds 100 mg daily. Maximum antidepressant effects may not occur for 2 or more weeks after therapy is begun.
After symptoms are controlled, dosage should be gradually reduced to the lowest level which will maintain relief of symptoms. If maintenance therapy is necessary, the manufacturer recommends 50-150 mg daily, preferably administered as a single daily dose at bedtime. Maintenance therapy should be continued for at least 3 months to prevent relapse.
Patients should be monitored for possible worsening of depression, suicidality, or unusual changes in behavior, especially at the beginning of therapy or during periods of dosage adjustment. (See Cautions: Precautions and Contraindications, in the Tricyclic Antidepressants General Statement 28:16.04.28.)
Trimipramine maleate is administered orally. Although trimipramine maleate has been administered in up to 4 divided doses throughout the day, it is long-acting and, when daily dosage does not exceed 200 mg, the entire daily dose may be administered at one time. Administration of most or all of the daily dosage at bedtime may reduce daytime sedation.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| TRIMIPRAMINE MALEATE 25 MG CAP | Maintenance | Adults take 2 capsules (50 mg) by oral route once daily at bedtime |
| TRIMIPRAMINE MALEATE 50 MG CAP | Maintenance | Adults take 1 capsule (50 mg) by oral route once daily at bedtime |
| TRIMIPRAMINE MALEATE 100 MG CP | Maintenance | Adults take 1 capsule (100 mg) by oral route once daily at bedtime |
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| TRIMIPRAMINE MALEATE 25 MG CAP | Maintenance | Adults take 2 capsules (50 mg) by oral route once daily at bedtime |
| TRIMIPRAMINE MALEATE 50 MG CAP | Maintenance | Adults take 1 capsule (50 mg) by oral route once daily at bedtime |
| TRIMIPRAMINE MALEATE 100 MG CP | Maintenance | Adults take 1 capsule (100 mg) by oral route once daily at bedtime |
The following drug interaction information is available for TRIMIPRAMINE MALEATE (trimipramine maleate):
There are 4 contraindications.
These drug combinations generally should not be dispensed or administered to the same patient. A manufacturer label warning that indicates the contraindication warrants inclusion of a drug combination in this category, regardless of clinical evidence or lack of clinical evidence to support the contraindication.
| Drug Interaction | Drug Names |
|---|---|
| Tricyclic; Tetracyclic Compounds/MAOIs SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Some MAO inhibitors may enhance the effects of tricyclic and tetracyclic compounds indirectly through inhibition of microsomal enzymes.(1) Tricyclic and tetracyclic compounds may sensitize post-synaptic receptors to amines that are accumulating extraneuronally as a result of MAO inhibition.(2) Similarity between cyclobenzaprine and TCAs warrants consideration of TCA interactions for cyclobenzaprine.(6) Mirtazapine, a tetracyclic antidepressant, should also be considered for this interaction.(7) Furazolidone is known to inhibit MAO. CLINICAL EFFECTS: Concurrent use may result in a severe reaction including hyperpyrexia, convulsions, excitability, fluctuations in blood pressure, convulsions, grand mal seizures, serotonin syndrome, coma, and death.(1,3-10) Symptoms of serotonin syndrome may include tremor, agitation, diaphoresis, hyperreflexia, clonus, tachycardia, hyperthermia, and muscle rigidity.(11) PREDISPOSING FACTORS: High doses of tricyclics or tetracyclics, or concurrent use of multiple drugs which increase CNS serotonin levels may increase risk for serotonin syndrome. PATIENT MANAGEMENT: The concurrent use of tricyclic antidepressants, cyclobenzaprine or mirtazapine and MAO inhibitors is contraindicated by the manufacturers of tricyclic antidepressants, cyclobenzaprine, mirtazapine, and tranylcypromine.(1,3-10) The manufacturers of tricyclic antidepressants, cyclobenzaprine and mirtazapine recommend at least 14 days between switching therapies.(1,3-9) The manufacturer of tranylcypromine recommends a medication-free interval of at least a week when initiating tranylcypromine in patients who have previously received a tricyclic antidepressant, then initiating tranylcypromine at a reduced dosage of 50% for one week.(10) The US manufacturer of phenelzine states that at least 14 days should elapse between the discontinuation of phenelzine and the initiation of another antidepressant. If phenelzine is used concurrently with or within 10 days of another antidepressant, the patient should be cautioned regarding the possibility of an adverse drug interaction.(8) The US manufacturer of selegiline states that at least 14 days should elapse between the discontinuation of selegiline and the initiation of a tricyclic antidepressant.(9) In emergency situations in patients maintained on tricyclics or tetracyclics, weigh the availability and safety of alternatives to methylene blue against the risk of serotonin syndrome. If methylene blue therapy is required, the patient's tricyclic, cyclobenzaprine or tetracyclic should be immediately discontinued. Patients should be monitored for serotonin syndrome for 2 weeks or until 24 hours after the last dose of methylene blue, whichever comes first.(12) In non-emergency situations in patients maintained on tricyclics, cyclobenzaprine or tetracyclics when methylene blue therapy is planned, discontinue the patient's tricyclic or tetracyclic at least 2 weeks in advance of methylene blue therapy. The patient's tricyclic or tetracyclic therapy may be resumed 24 hours after the last dose of linezolid or methylene blue.(12) Do not initiate tricyclic, cyclobenzaprine or tetracyclic therapy in patients receiving methylene blue until 24 hours after the last dose of these agents.(12) If concurrent therapy is warranted, patients should be monitored for signs and symptoms of serotonin syndrome. Instruct patients to report muscle twitching, tremors, shivering and stiffness, fever, heavy sweating, heart palpitations, restlessness, confusion, agitation, trouble with coordination, or severe diarrhea. DISCUSSION: It should be noted that if this interaction occurs, the consequences will be immediate and severe. Effects may continue to be seen for several days after discontinuing the MAOI. The interaction has been reported with tricyclic antidepressants and selegiline.(9) Methylene blue, when administered intravenously, has been shown to reach sufficient concentrations to be a potent inhibitor of MAO-A.(14,15) Metaxalone is a weak inhibitor of MAO.(34,35) The FDA AERS contains reports of serotonin syndrome with concurrent injectable methylene blue and citalopram, clomipramine, escitalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine. The risk of serotonin syndrome with other psychiatric drugs is unclear.(13) One or more of the drug pairs linked to this monograph have been included in a list of interactions that should be considered "high-priority" for inclusion and should not be inactivated in EHR systems. This DDI subset was vetted by an expert panel commissioned by the U.S. Office of the National Coordinator (ONC) for Health Information Technology. |
AZILECT, EMSAM, FURAZOLIDONE, MARPLAN, MATULANE, METAXALONE, METHYLENE BLUE, NARDIL, PARNATE, PHENELZINE SULFATE, PROCARBAZINE HCL, PROVAYBLUE, RASAGILINE MESYLATE, SELEGILINE HCL, TRANYLCYPROMINE SULFATE, XADAGO, ZELAPAR |
| Pimozide/Tricyclic Compounds SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Concurrent use may possibly result in additive effects on the QTc interval.(1) CLINICAL EFFECTS: Concurrent use may result in prolongation of the QTc interval, which may result in potentially life-threatening arrhythmias.(1) PREDISPOSING FACTORS: The risk of QT prolongation or torsades de pointes may be increased in patients with cardiovascular disease (e.g. heart failure, myocardial infarction, history of torsades de pointes, congenital long QT syndrome), hypokalemia, hypomagnesemia, hypocalcemia, bradycardia, female gender, or advanced age.(2) Concurrent use of more than one drug known to cause QT prolongation or higher systemic concentrations of either QT prolonging drug are additional risk factors for torsades de pointes. Factors which may increase systemic drug concentrations include rapid infusion of an intravenous dose or impaired metabolism or elimination of the drug (e.g. coadministration with an agent which inhibits its metabolism or elimination, genetic impairment in drug metabolism or elimination, and/or renal/hepatic dysfunction).(2) PATIENT MANAGEMENT: Concurrent therapy with pimozide and tricyclic antidepressants should be avoided. The manufacturer of pimozide states that concurrent therapy with agents that prolong the QTc interval is contraindicated.(1) If concurrent therapy is deemed medically necessary, consider obtaining serum calcium, magnesium, and potassium levels and monitoring ECG at baseline and at regular intervals. Correct any electrolyte abnormalities. Instruct patients to report any irregular heartbeat, dizziness, or fainting. DISCUSSION: There is no clinical documentation to support this interaction. Pimozide has been shown to prolong the QTc interval. Therefore, the manufacturer of pimozide states that concurrent therapy with agents that prolong the QTc interval is contraindicated because of the risk of additive effects on the QTc interval.(1) No other clinical documentation is available. |
PIMOZIDE |
| Iomeprol/Selected Antidepressants SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Both iomeprol and selected antidepressants may lower the seizure threshold.(1) CLINICAL EFFECTS: Use of iomeprol in a patient receiving selected antidepressants may increase the risk of seizure.(1) Antidepressants included in this monograph are tricyclic antidepressants (except formulations which also include benzodiazepines), bupropion, and oral monoamine oxidase(MAO) inhibitors used to treat depression. PREDISPOSING FACTORS: Iomeprol associated seizures are more likely in patients with intracranial tumors or epilepsy.(1) PATIENT MANAGEMENT: The manufacturer of iomeprol states that tricyclic antidepressants and MAO inhibitors should be discontinued 48 hours before iomeprol use. Treatment with an antidepressant should not be resumed until 24 hours post-procedure.(1) The UK manufacturer of bupropion states that it must not be used in the presence of predisposing risk factors such as medicinals which are known to lower the seizure threshold unless there is a compelling clinical justification that concurrent use outweighs the potential increased risk of seizure.(2) DISCUSSION: Because selected antidepressants may lower seizure threshold, antidepressants should be discontinued 48 hours before iomeprol use. Treatment with an antidepressant should not be resumed until 24 hours post-procedure.(1) |
IOMERON 350 |
| Selected CYP2D6 Substrates/Mavorixafor SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Mavorixafor is a strong inhibitor of CYP2D6 and is expected to inhibit the metabolism of agents through this pathway.(1) CLINICAL EFFECTS: Concurrent use of mavorixafor may result in elevated levels of and toxicity from agents metabolized by CYP2D6.(1) PREDISPOSING FACTORS: With tricyclic antidepressants, the risk of seizures may be increased in patients with a history of head trauma or prior seizure; CNS tumor; severe hepatic cirrhosis; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; use of over-the-counter stimulants and anorectics; diabetics treated with oral hypoglycemics or insulin; or with concomitant medications known to lower seizure threshold (antipsychotics, theophylline, systemic steroids). With anticholinergic agents, the risk of anticholinergic toxicities including cognitive decline, delirium, falls and fractures is increased in geriatric patients using more than one medicine with anticholinergic properties.(2) PATIENT MANAGEMENT: The US manufacturer of mavorixafor states concurrent use with CYP2D6 substrate that are highly dependent on CYP2D6 metabolism is contraindicated.(1) DISCUSSION: Mavorixafor (400 mg) increased dextromethorphan (CYP2D6 substrate) maximum concentration (Cmax) and area-under-curve (AUC) by 6-fold and 9-fold, respectively.(1) Selected CYP2D6 substrates linked to this monograph include: aripiprazole, brexpiprazole, desipramine, deutetrabenazine, dextromethorphan, doxepin, encainide, fenfluramine, metoclopramide, methoxyphenamine, metoprolol, mexiletine, nebivolol, paroxetine, perphenazine, risperidone, tetrabenazine, trimipramine, venlafaxine, and yohimbine. |
XOLREMDI |
There are 17 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Guanethidine; Guanadrel/Tricyclic Compounds SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Uptake of guanethidine is blocked by tricyclic antidepressants at the adrenergic neuron. CLINICAL EFFECTS: Concurrent use of tricyclic antidepressants may result in decreased guanethidine or guanadrel effectiveness. The effects may be seen for several days after discontinuation of the tricyclic antidepressant. PREDISPOSING FACTORS: Possibly concurrent administration of drugs that inhibit hepatic enzymes. PATIENT MANAGEMENT: Avoid concomitant administration of these drugs. If both drugs are administered, adjust the guanethidine dose as needed based on blood pressure. DISCUSSION: This interaction is well documented. Similarity between cyclobenzaprine and TCA's warrants consideration of TCA interactions for cyclobenzaprine. |
GUANETHIDINE HEMISULFATE |
| Select Indirect-Acting Sympathomimetics/Tricyclic Compounds SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Unknown. However, it is speculated that indirect-acting sympathomimetics would have decreased activity due to tricyclic blockage of their uptake into the adrenergic neuron. CLINICAL EFFECTS: Decreased effect of indirect acting sympathomimetics. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Use of tricyclic compounds and indirect-acting sympathomimetics should be approached with caution. Montior patients receiving concurrent therapy for decreased sympathomimetic efficacy. DISCUSSION: The pressor effects of the indirect-acting sympathomimetic amines (e.g., amphetamines, ephedrine, and methylphenidate) are antagonized by tricyclic antidepressants. |
ADDERALL, ADDERALL XR, ADIPEX-P, ADZENYS XR-ODT, AKOVAZ, AMPHETAMINE SULFATE, APTENSIO XR, AZSTARYS, BENZPHETAMINE HCL, CONCERTA, COTEMPLA XR-ODT, DAYTRANA, DESOXYN, DEXEDRINE, DEXMETHYLPHENIDATE HCL, DEXMETHYLPHENIDATE HCL ER, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE ER, DEXTROAMPHETAMINE-AMPHET ER, DEXTROAMPHETAMINE-AMPHETAMINE, DIETHYLPROPION HCL, DIETHYLPROPION HCL ER, DROXIDOPA, DYANAVEL XR, EMERPHED, EPHEDRINE HCL, EPHEDRINE SULFATE, EPHEDRINE SULFATE-0.9% NACL, EPHEDRINE SULFATE-NACL, EVEKEO, FINTEPLA, FOCALIN, FOCALIN XR, JORNAY PM, LISDEXAMFETAMINE DIMESYLATE, LOMAIRA, METADATE CD, METADATE ER, METHAMPHETAMINE HCL, METHYLIN, METHYLPHENIDATE, METHYLPHENIDATE ER, METHYLPHENIDATE ER (LA), METHYLPHENIDATE HCL, METHYLPHENIDATE HCL CD, METHYLPHENIDATE HCL ER (CD), MYDAYIS, NORTHERA, PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE ER, PHENTERMINE HCL, PROCENTRA, QSYMIA, QUILLICHEW ER, QUILLIVANT XR, RELEXXII, REZIPRES, RITALIN, RITALIN LA, TETRAHYDROZOLINE HCL, VYVANSE, XELSTRYM, ZENZEDI |
| Tapentadol/Tricyclic Compounds; Carbamazepine SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Tapentadol and tricyclic compounds may lower the seizure threshold.(1) Tapentadol and tricyclic compounds may result in additive effects on serotonin levels.(1) Although not used therapeutically as an antidepressant, carbamazepine is a tricyclic compound. CLINICAL EFFECTS: Concurrent use of tapentadol and a tricyclic compound may result in seizures or serotonin syndrome.(1) PREDISPOSING FACTORS: Risk of seizures may be increased in patients with epilepsy, a history of seizures, head trauma, metabolic disorders, alcohol or drug withdrawal, or infections of the central nervous system.(1) PATIENT MANAGEMENT: Tapentadol should be used with caution in patients taking tricyclic compounds, including carbamazepine. Monitor patients closely for serotonin syndrome.(1) DISCUSSION: Concurrent use of tapentadol with tricyclic compounds may result in additive blockage of serotonin reuptake, leading to central serotonergic hyperstimulation. Cases of serotonin syndrome have been reported with tapentadol in combination with other serotonergic drugs.(1) Use of tapentadol has been associated with increased seizure frequency in patients with seizure disorders.(1) |
NUCYNTA, NUCYNTA ER |
| Solid Oral Potassium Tablets/Anticholinergics SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Concentrated potassium may damage the lining of the GI tract. Anticholinergics delay gastric emptying, resulting in the potassium product remaining in the gastrointestinal tract for a longer period of time.(1-16) CLINICAL EFFECTS: Use of solid oral dosage forms of potassium in patients treated with anticholinergics may result in gastrointestinal erosions, ulcers, stenosis and bleeding.(1-16) PREDISPOSING FACTORS: Diseases or conditions which may increase risk for GI damage include: preexisting dysphagia, strictures, cardiomegaly, diabetic gastroparesis, elderly status, or insufficient oral intake to allow dilution of potassium.(1-10,21) Other drugs which may add to risk for GI damage include: nonsteroidal anti-inflammatory drugs (NSAIDs), bisphosphonates, or tetracyclines.(21) PATIENT MANAGEMENT: Regulatory agency and manufacturer recommendations regarding this interaction: - In the US, all solid oral dosage forms (including tablets and extended release capsules) of potassium are contraindicated in patients receiving anticholinergics at sufficient dosages to result in systemic effects.(2-8) Patients receiving such anticholinergic therapy should use a liquid form of potassium chloride.(2) - In Canada, solid oral potassium is contraindicated in any patient with a cause for arrest or delay in tablet/capsule passage through the gastrointestinal tract and the manufacturers recommend caution with concurrent anticholinergic medications.(1,9-10) Evaluate each patient for predisposing factors which may increase risk for GI damage. In patients with multiple risk factors for harm, consider use of liquid potassium supplements, if tolerated. For patients receiving concomitant therapy, assure any potassium dose form is taken after meals with a large glass of water or other fluid. To decrease potassium concentration in the GI tract, limit each dose to 20 meq; if more than 20 meq daily is required, give in divided doses.(2) If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. Patients should be instructed to immediately report any difficulty swallowing, abdominal pain, distention, severe vomiting, or gastrointestinal bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling. DISCUSSION: In clinical trials, there was a higher incidence of gastric and duodenal lesions in patients receiving a high dose of a wax-matrix controlled-release formulation with a concurrent anticholinergic agent. Some lesions were asymptomatic and not accompanied by bleeding, as shown by a lack of positive Hemoccult tests.(1-17) Several studies suggest that the incidence of gastric and duodenal lesions may be less with the microencapsulated formulation of potassium chloride.(14-17) |
KLOR-CON 10, KLOR-CON 8, KLOR-CON M10, KLOR-CON M15, KLOR-CON M20, POTASSIUM CHLORIDE, POTASSIUM CITRATE ER, UROCIT-K |
| Solid Oral Potassium Capsules/Anticholinergics SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Concentrated potassium may damage the lining of the GI tract. Anticholinergics delay gastric emptying, resulting in the potassium product remaining in the gastrointestinal tract for a longer period of time.(1-16)) CLINICAL EFFECTS: Use of solid oral dosage forms of potassium in patients treated with anticholinergics may result in gastrointestinal erosions, ulcers, stenosis and bleeding.(1-16) PREDISPOSING FACTORS: Diseases or conditions which may increase risk for GI damage include: preexisting dysphagia, strictures, cardiomegaly, diabetic gastroparesis, elderly status, or insufficient oral intake to allow dilution of potassium.(1-10,21) Other drugs which may add to risk for GI damage include: nonsteroidal anti-inflammatory drugs (NSAIDs), bisphosphonates, or tetracyclines.(21) PATIENT MANAGEMENT: Regulatory agency and manufacturer recommendations regarding this interaction: - In the US, all solid oral dosage forms (including tablets and extended release capsules) of potassium are contraindicated in patients receiving anticholinergics at sufficient dosages to result in systemic effects.(2-8) Patients receiving such anticholinergic therapy should use a liquid form of potassium chloride.(2) - In Canada, solid oral potassium is contraindicated in any patient with a cause for arrest or delay in tablet/capsule passage through the gastrointestinal tract and the manufacturers recommend caution with concurrent anticholinergic medications.(1,9-10) Evaluate each patient for predisposing factors which may increase risk for GI damage. In patients with multiple risk factors for harm, consider use of liquid potassium supplements, if tolerated. For patients receiving concomitant therapy, assure any potassium dose form is taken after meals with a large glass of water or other fluid. To decrease potassium concentration in the GI tract, limit each dose to 20 meq; if more than 20 meq daily is required, give in divided doses.(2) If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. Patients should be instructed to immediately report any difficulty swallowing, abdominal pain, distention, severe vomiting, or gastrointestinal bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling. DISCUSSION: In clinical trials, there was a higher incidence of gastric and duodenal lesions in patients receiving a high dose of a wax-matrix controlled-release formulation with a concurrent anticholinergic agent. The lesions were asymptomatic and not accompanied by bleeding, as shown by a lack of positive Hemoccult tests.(1-17) Several studies suggest that the incidence of gastric and duodenal lesions may be less with the microencapsulated formulation of potassium chloride.(14-17) |
POTASSIUM CHLORIDE |
| Sodium Oxybate/Agents that May Cause Respiratory Depression SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Oxybate by itself may be associated with severe somnolence or respiratory depression. Concurrent use with other CNS depressants may further increase the risk for respiratory depression or loss of consciousness.(1-3) CLINICAL EFFECTS: Concurrent use of sodium oxybate and sedative hypnotics or alcohol may further increase the risk for profound sedation, respiratory depression, coma, and/or death.(1,2) Fatalities have been reported.(3) PREDISPOSING FACTORS: Based upon FDA evaluation of deaths in patients taking sodium oxybate, risk factors may include: use of multiple drugs which depress the CNS, more rapid than recommended oxybate dose titration, exceeding the maximum recommended oxybate dose, and prescribing for unapproved uses such as fibromyalgia, insomnia or migraine. Note that in oxybate clinical trials for narcolepsy 78% - 85% of patients were also receiving concomitant CNS stimulants.(1-3) PATIENT MANAGEMENT: Avoid use of concomitant opioids, benzodiazepines, sedating antidepressants, sedating antipsychotics, general anesthetics, or muscle relaxants, particularly when predisposing risk factors are present. If combination use is required, dose reduction or discontinuation of one or more CNS depressants should be considered. If short term use of an opioid or general anesthetic is required, consider interruption of sodium oxybate treatment.(1,2) Respiratory depression can occur at any time during opioid therapy, especially during therapy initiation and following dosage increases. Consider this risk when using concurrently with other agents that may cause CNS depression.(4) Discuss naloxone with all patients when prescribing or renewing an opioid analgesic or medicine to treat opioid use disorder (OUD). Consider prescribing naloxone to patients prescribed medicines to treat OUD or opioid analgesics (such as those taking CNS depressants) who are at increased risk of opioid overdose and when a patient has household members/close contacts at risk for accidental overdose.(5) DISCUSSION: The FDA evaluated sodium oxybate postmarket fatal adverse event reports from the FDA Adverse Event Reporting System(AERS)and from the manufacturer. Although report documentation was not always optimal or complete, useful information was obtained. Factors which may have contributed to fatal outcome: concomitant use of one or more drugs which depress the CNS, more rapid than recommended oxybate dose titration, exceeding the maximum recommended oxybate dose, and prescribing for unapproved uses such as fibromyalgia, insomnia or migraine. Many deaths occurred in patients with serious psychiatric disorders such as depression and substance abuse. Other concomitant diseases may have also contributed to respiratory and CNS depressant effects of oxybate.(3) |
LUMRYZ, LUMRYZ STARTER PACK, SODIUM OXYBATE, XYREM, XYWAV |
| Higher Strength Tricyclics;Trazodone/Fluoxetine; Paroxetine SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Depending upon the interacting combination, pharmacokinetic and/or pharmacodynamic interactions are possible. Fluoxetine is a moderate inhibitor of CYP2C19 and a strong inhibitor of CYP2D6.(1) Paroxetine is a strong inhibitor of CYP2D6.(1,2) Amitriptyline, clomipramine, doxepin, imipramine and trimipramine are metabolized by CYP2C19 and CYP2D6.(1) Desipramine and nortriptyline are metabolized by CYP2D6.(1) Trazodone is metabolized by CYP3A4 and its metabolite, mCPP, is pharmacologically active. MCPP is metabolized by CYP2D6 and when it accumulates may be associated with adverse effects. Fluoxetine, paroxetine, clomipramine, and imipramine significantly increase neuronal serotonin levels. CLINICAL EFFECTS: Concurrent administration of fluoxetine or paroxetine with selected cyclic agents which are metabolized by CYP2D6 or CYP2C19 may result in an increase in serum levels, toxicities (e.g. risk for seizures, severe anticholinergic effects), and/or clinical effects of the tricyclic agent or trazodone. Elevated levels of tricyclics and trazodone may increase the risk of QT prolongation and the risk for torsades de pointes. Concurrent administration of fluoxetine or paroxetine with clomipramine, and perhaps with imipramine, high dose amitriptyline, or trazodone may increase the risk for serotonin syndrome. PREDISPOSING FACTORS: Higher doses or higher systemic concentrations of fluoxetine or paroxetine may increase the magnitude of this interaction. Concurrent use of multiple drugs which increase CNS serotonin levels would be expected to further increase risk for serotonin syndrome.(21) The risk of QT prolongation or torsades de pointes may be increased in patients with cardiovascular disease (e.g. heart failure, myocardial infarction, history of torsades de pointes, congenital long QT syndrome), hypokalemia, hypomagnesemia, hypocalcemia, bradycardia, female gender, or advanced age.(20) Concurrent use of more than one drug known to cause QT prolongation or higher systemic concentrations of either QT prolonging drug are additional risk factors for torsades de pointes. Factors which may increase systemic drug concentrations include rapid infusion of an intravenous dose or impaired metabolism or elimination of the drug (e.g. coadministration with an agent which inhibitors its metabolism or elimination, genetic impairment in drug metabolism or elimination, and/or renal/hepatic dysfunction).(20) The risk of seizures may be increased in patients with a history of head trauma or prior seizure; CNS tumor; severe hepatic cirrhosis; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; use of over-the-counter stimulants and anorectics; diabetics treated with oral hypoglycemics or insulin; or with concomitant medications known to lower seizure threshold (antipsychotics, theophylline, systemic steroids). The risk of anticholinergic toxicities including cognitive decline, delirium, falls and fractures is increased in geriatric patients using more than one medicine with anticholinergic properties.(22) PATIENT MANAGEMENT: Patients should be observed for increased adverse effects and clinical effects of tricyclic compounds or trazodone at the initiation of concurrent therapy with fluoxetine or paroxetine. Plasma concentrations of the tricyclic compound (e.g. imipramine/desipramine, amitriptyline/nortriptyline) should be monitored and the dosage adjusted accordingly. If fluoxetine or paroxetine is discontinued in a patient receiving a cyclic antidepressant, the dosage may need to be adjusted upward as the effects of enzyme inhibition wane. The effects of fluoxetine on hepatic metabolism may last for up to 5 weeks after fluoxetine discontinuation. A cyclic antidepressant started after the discontinuation of fluoxetine should be started at a lower initial dosage. Patients receiving fluoxetine or paroxetine and clomipramine, imipramine, or higher dose amitriptyline should be monitored for serotonin syndrome. Mild serotonin symptoms may include: shivering, diaphoresis, mydriasis, intermittent tremor, and/or myoclonus. Moderate serotonin symptoms may include: tachycardia, hypertension, hyperthermia, mydriasis, diaphoresis, hyperactive bowel sounds, hyperreflexia, and/OR clonus. Severe serotonin symptoms may include: severe hypertension and tachycardia, shock, agitated delirium, muscular rigidity, and/or hypertonicity. When concurrent therapy may be associated with QT prolongation, consider obtaining serum calcium, magnesium, and potassium levels and monitoring ECG at baseline and at regular intervals. Correct any electrolyte abnormalities. Instruct patients to report any irregular heartbeat, dizziness, and fainting. DISCUSSION: Case reports have shown that the addition of fluoxetine to a tricyclic compound therapy can result in an increase of 100-300% in the tricyclic compound plasma concentration as well as an increase in adverse effects, including seizures and delirium. In an 83 year-old patient, the combination of clomipramine and fluoxetine resulted in high clomipramine concentrations and cardiac side effects. In a 70 year old patient, the use of venlafaxine, fluoxetine, and nortriptyline was associated with severe anticholinergic side effects. This interaction was thought to be due to increased nortriptyline levels. There is one case report of serotonin syndrome during concurrent therapy with paroxetine and trazodone.(23) There have also been case reports of serotonin syndrome with trazodone and fluoxetine,(25) trazodone and amitriptyline with lithium, and cyclobenzaprine(structurally related to the TCAs) with duloxetine. In a 24 year-old patient, the use of fluoxetine and trazodone resulted in severe irritability, anger, anxiety, and anorexia.(24) In a study in 11 patients, concurrent administration of trazodone 100 mg/day and fluoxetine 20 mg/day increased the concentrations of trazodone and its active metabolite mCPP by 65% and 231%.(25) QTc prolongation also exists with some antidepressants. In a case report, the combination of levofloxacin, imipramine, and fluoxetine was associated with a QTc of 509msec. The authors concluded that this interaction was due to the pharmacodynamic additive effect among fluoxetine, imipramine, and levofloxacin. Cyclic antidepressants included in this monograph are amitriptyline (> 40 mg), clomipramine (> 25 mg), desipramine (all strengths), doxepin (> 25 mg), imipramine (> 10 mg), nortriptyline (> 30 mg), trazodone (> 75 mg), and trimipramine (> 25 mg). |
FLUOXETINE DR, FLUOXETINE HCL, OLANZAPINE-FLUOXETINE HCL, PAROXETINE CR, PAROXETINE ER, PAROXETINE HCL, PAROXETINE MESYLATE, PAXIL, PAXIL CR, PROZAC |
| Selected Direct-Acting Sympathomimetics/Tricyclic Compounds SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Unknown. However, it is speculated that direct-acting sympathomimetic amines have an enhanced effect due to tricyclic blockage of norepinephrine reuptake. CLINICAL EFFECTS: Increased effect of direct acting sympathomimetics. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Consider avoiding the concurrent use of direct-acting sympathomimetics and tricyclic compounds. If concurrent use of direct-acting sympathomimetics and tricyclic compounds is warranted, the initial dose of the sympathomimetic should be lowered and the patient should be monitored for adverse cardiovascular effects. Use of tricyclic compounds and other sympathomimetics should be approached with caution. DISCUSSION: Epinephrine and other direct-acting sympathomimetic amines exert enhanced cardiovascular effects (e.g., arrhythmias, hypertension, and tachycardia) in individuals concurrently receiving or previously treated with tricyclic antidepressants. Other direct and mixed acting sympathomimetic amines have also been reported to interact with tricyclic antidepressants. These include norepinephrine, phenylephrine, dopamine, and methoxamine. Protriptyline, amitriptyline, and desipramine have also been reported to interact with direct-acting sympathomimetics. |
ADRENALIN, ALBUTEROL SULFATE, ARTICADENT DENTAL, ARTICAINE-EPINEPHRINE, ARTICAINE-EPINEPHRINE BIT, BIORPHEN, BUFFERED LIDOCAINE-EPINEPHRINE, BUPIVACAINE HCL-EPINEPHRINE, BUPIVACAINE-DEXAMETH-EPINEPHRN, CITANEST FORTE DENTAL, DOBUTAMINE HCL, DOBUTAMINE HCL-D5W, DOPAMINE HCL, DOPAMINE HCL IN 5% DEXTROSE, EPINEPHRINE, EPINEPHRINE BITARTR-0.9% NACL, EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE-NACL, EPINEPHRINE CONVENIENCE KIT, EPINEPHRINE HCL-0.9% NACL, EPINEPHRINE HCL-D5W, EPINEPHRINE-0.9% NACL, EPINEPHRINE-D5W, EPINEPHRINE-NACL, FORMOTEROL FUMARATE, IMMPHENTIV, ISOPROTERENOL HCL, ISOPROTERENOL HCL-0.9% NACL, ISUPREL, LEVOPHED, LIDOCAINE HCL-EPINEPHRINE, LIDOCAINE HCL-EPINEPHRINE-NACL, LIDOCAINE-EPINEPHRINE, LIGNOSPAN STANDARD, MARCAINE-EPINEPHRINE, MIDODRINE HCL, NOREPINEPHRINE BITAR-0.9% NACL, NOREPINEPHRINE BITARTRAT-WATER, NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE-D5W, ORABLOC, OXYMETAZOLINE HCL, PHENYLEPHRINE HCL, PHENYLEPHRINE HCL-0.9% NACL, PHENYLEPHRINE HCL-NACL, PHENYLEPHRINE HCL-WATER, PROMETHAZINE VC, PROMETHAZINE-PHENYLEPHRINE HCL, R.E.C.K.(ROPIV-EPI-CLON-KETOR), RACEPINEPHRINE HCL, SENSORCAINE-EPINEPHRINE, SENSORCAINE-MPF EPINEPHRINE, SEPTOCAINE, TERBUTALINE SULFATE, VAZCULEP, VIVACAINE, XYLOCAINE DENTAL-EPINEPHRINE, XYLOCAINE WITH EPINEPHRINE, XYLOCAINE-MPF WITH EPINEPHRINE, XYLOMETAZOLINE HCL |
| Select Mixed Acting Sympathomimetics/Tricyclic Compounds SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Unknown. However, it is speculated that mixed acting sympathomimetics will show effects based on the predominance of either direct or indirect activity. Agents with predominate effects of direct-acting sympathomimetic amines are expected to have an enhanced effect due to tricyclic blockage of norepinephrine reuptake. Agents with predominate effects of indirect-acting sympathomimetics would have decreased activity due to tricyclic blockage of their uptake into the adrenergic neuron. CLINICAL EFFECTS: Mixed acting sympathomimetics will show effects based on the predominance of either direct or indirect activity. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Consider avoiding the concurrent use of mixed-acting sympathomimetics and tricyclic compounds. If concurrent is warranted, the initial dose of the sympathomimetic should be lowered and the patient should be monitored for adverse cardiovascular effects. DISCUSSION: Epinephrine and other direct-acting sympathomimetic amines exert enhanced cardiovascular effects (e.g., arrhythmias, hypertension, and tachycardia) in individuals concurrently receiving or previously treated with tricyclic antidepressants. Other direct and mixed acting sympathomimetic amines have also been reported to interact with tricyclic antidepressants. These include norepinephrine, phenylephrine, dopamine, and methoxamine. The pressor effects of the indirect-acting sympathomimetic amines (i.e., amphetamines, ephedrine, methylphenidate, pseudoephedrine, and tyramine) are antagonized by tricyclic antidepressants. Protriptyline, amitriptyline, and desipramine have also been reported to interact with direct-acting sympathomimetics. |
ISOMETHEPTENE MUCATE |
| Iobenguane I 123/Agents that Affect Catecholamines SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Many compounds that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells.(1) CLINICAL EFFECTS: Compounds that reduce catecholamine uptake or that deplete catecholamine stores may interfere with imaging completed with iobenguane.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Discuss the use of agents that affect catecholamines. Discontinue drugs that reduce catecholamine uptake or deplete catecholamine stores prior to imaging with iobenguane. Before imaging with iobenguane, discontinue agents that affect catecholamines for at least 5 biological half-lives, as clinically tolerated.(1) DISCUSSION: Many agents may reduce catecholamine uptake or deplete catecholamine stores.(1) Examples include: - CNS stimulants or amphetamines (e.g. cocaine, methylphenidate, dextroamphetamine) - norepinephrine and dopamine reuptake inhibitors (e.g. phentermine) - norepinephrine and serotonin reuptake inhibitors (e.g. tramadol) - monoamine oxidase inhibitors (e.g. phenelzine, linezolid) - central monoamine depleting drugs (e.g. reserpine) - non-select beta adrenergic blocking drugs (e.g. labetalol) - alpha agonists or alpha/beta agonists (e.g. pseudoephedrine, phenylephrine, ephedrine, phenylpropanolamine, naphazoline) - tricyclic antidepressants or norepinephrine reuptake inhibitors (e.g. amitriptyline, bupropion, duloxetine, mirtazapine, venlafaxine) - botanicals that may inhibit reuptake of norepinephrine, serotonin or dopamine (e.g. ephedra, ma huang, St. John's Wort, yohimbine) |
ADREVIEW |
| Selected CYP2D6 Substrates/Panobinostat SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Panobinostat is a moderate inhibitor of CYP2D6 and is expected to inhibit the metabolism of agents through this pathway.(1) CLINICAL EFFECTS: Concurrent use of panobinostat may result in elevated levels of and toxicity from agents metabolized by CYP2D6.(1) PREDISPOSING FACTORS: With tricyclic antidepressants, the risk of seizures may be increased in patients with a history of head trauma or prior seizure; CNS tumor; severe hepatic cirrhosis; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; use of over-the-counter stimulants and anorectics; diabetics treated with oral hypoglycemics or insulin; or with concomitant medications known to lower seizure threshold (antipsychotics, theophylline, systemic steroids). With anticholinergic agents, the risk of anticholinergic toxicities including cognitive decline, delirium, falls and fractures is increased in geriatric patients using more than one medicine with anticholinergic properties.(4) PATIENT MANAGEMENT: Avoid the concurrent use of panobinostat with agents that are sensitive CYP2D6 or CYP2D6 substrates with a narrow therapeutic index. If concurrent use is warranted, monitor patients for toxicity.(1) DISCUSSION: In a study in 14 subjects with advanced cancer, panobinostat (20 mg daily on Days 3, 5, and 8) increased the maximum concentration (Cmax) and area-under-curve (AUC) of a single dose of dextromethorphan (60 mg) by 20-200% and 20-130%, respectively. Dextromethorphan exposures were extremely variable.(1) Selected CYP2D6 substrates linked to this monograph include: desipramine, deutetrabenazine, dextromethorphan, doxepin, encainide, methoxyphenamine, metoprolol, nebivolol, paroxetine, perphenazine, risperidone, tetrabenazine, trimipramine, venlafaxine, and yohimbine. |
FARYDAK |
| Selected CYP1A2 or CYP2D6 Substrates/Givosiran SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Givosiran interferes with the first and rate-limiting step in hepatic heme biosynthesis, which may lower hepatic heme levels and decrease production and/or activity of cytochrome P450 enzymes.(1,2) CLINICAL EFFECTS: Concurrent use of givosiran may result in elevated levels of and toxicity from agents metabolized by CYP1A2 or CYP2D6.(1) PREDISPOSING FACTORS: With tricyclic antidepressants, the risk of seizures may be increased in patients with a history of head trauma or prior seizure; CNS tumor; severe hepatic cirrhosis; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; use of over-the-counter stimulants and anorectics; diabetics treated with oral hypoglycemics or insulin; or with concomitant medications known to lower seizure threshold (antipsychotics, theophylline, systemic steroids). With anticholinergic agents, the risk of anticholinergic toxicities including cognitive decline, delirium, falls and fractures is increased in geriatric patients using more than one medicine with anticholinergic properties.(3) PATIENT MANAGEMENT: Avoid the concurrent use of givosiran with agents that are sensitive substrates of CYP1A2 or CYP2D6, or CYP1A2 or CYP2D6 substrates with a narrow therapeutic index. If concurrent use is unavoidable, decrease the dose of the CYP1A2 or CYP2D6 substrate and monitor patients for toxicity. DISCUSSION: A study of 9 patients with acute intermittent porphyria found that givosiran decreased the maximum concentration (Cmax) and area-under-curve (AUC) of caffeine (a CYP1A2 substrate) by 1.3- and 3.1-fold, respectively, compared to caffeine alone. Givosiran also decreased the Cmax and AUC of dextromethorphan (a CYP2D6 substrate) by 2- and 2.4-fold, respectively, compared to dextromethorphan alone.(1,2) Selected CYP2D6 substrates linked to this monograph include: desipramine, deutetrabenazine, dextromethorphan, doxepin, encainide, methoxyphenamine, metoprolol, nebivolol, nefazodone, paroxetine, perphenazine, risperidone, tetrabenazine, trimipramine, and venlafaxine. Selected CYP1A2 substrates linked to this monograph include: agomelatine, aminophylline, rasagiline, tacrine, theophylline, tizanidine, and yohimbine. |
GIVLAARI |
| Clozapine/Anticholinergics SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Clozapine has potent anticholinergic properties and inhibits serotonin receptors, including 5-HT3.(1-4) Both of these properties may cause inhibition of gastrointestinal (GI) smooth muscle contraction, resulting in decreased peristalsis.(3,4) These effects may be compounded by concurrent use of anticholinergic agents.(1-6) CLINICAL EFFECTS: Concurrent use of clozapine with other anticholinergic agents may increase the risk of constipation (common) and serious bowel complications (uncommon), including complete bowel obstruction, fecal impaction, paralytic ileus and intestinal ischemia or infarction.(1-6) PREDISPOSING FACTORS: The risk for serious bowel complications is higher with increasing age, higher frequency of constipation, and in patients on higher doses of clozapine or multiple anticholinergic agents.(1,5) PATIENT MANAGEMENT: Avoid the use of other anticholinergic agents with clozapine.(1-6) If concurrent use is necessary, evaluate the patient's bowel function regularly. Monitor for symptoms of constipation and GI hypomotility, including having bowel movements less than three times weekly or less than usual, difficulty having a bowel movement or passing gas, nausea, vomiting, and abdominal pain or distention.(2) Consider a prophylactic laxative in those with a history of constipation or bowel obstruction.(2) Review patient medication list for other anticholinergic agents. When possible, decrease the dosage or number of prescribed anticholinergic agents, particularly in the elderly. Counsel the patient about the importance of maintaining adequate hydration. Encourage regular exercise and eating a high-fiber diet.(2) DISCUSSION: In a prospective cohort study of 26,720 schizophrenic patients in the Danish Central Psychiatric Research Registry, the odds ratio (OR) for ileus was 1.99 with clozapine and 1.48 with anticholinergics. The OR for fatal ileus was 6.73 with clozapine and 5.88 with anticholinergics. Use of anticholinergics with 1st generation antipsychotics (FGA) increased the risk of ileus compare to FGA alone, but this analysis was not done with clozapine.(5) A retrospective cohort study of 24,970 schizophrenic patients from the Taiwanese National Health Insurance Research Database found that the hazard ratio (HR) for clozapine-induced constipation increased from 1.64 when clozapine is used alone, to 2.15 when used concomitantly with anticholinergics. However, there was no significant difference in the HR for ileus when clozapine is used with and without anticholinergics (1.95 and 2.02, respectively).(6) In the French Pharmacovigilance Database, 7 of 38 cases of antipsychotic-associated ischemic colitis or intestinal necrosis involved clozapine, and 5 of these cases involved use of concomitant anticholinergic agents. Three patients died, one of whom was on concomitant anticholinergics.(3) In a case series, 4 of 9 cases of fatal clozapine-associated GI dysfunction involved concurrent anticholinergic agents.(4) |
CLOZAPINE, CLOZAPINE ODT, CLOZARIL, VERSACLOZ |
| Eluxadoline/Anticholinergics; Opioids SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Eluxadoline is a mixed mu-opioid and kappa-opioid agonist and delta-opioid antagonist and may alter or slow down gastrointestinal transit.(1) CLINICAL EFFECTS: Constipation related adverse events that sometimes required hospitalization have been reported, including the development of intestinal obstruction, intestinal perforation, and fecal impaction.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Avoid use with other drugs that may cause constipation. If concurrent use is necessary, evaluate the patient's bowel function regularly. Monitor for symptoms of constipation and GI hypomotility, including having bowel movements less than three times weekly or less than usual, difficulty having a bowel movement or passing gas, nausea, vomiting, and abdominal pain or distention.(1) Instruct patients to stop eluxadoline and immediately contact their healthcare provider if they experience severe constipation. Loperamide may be used occasionally for acute management of severe diarrhea, but must be discontinued if constipation develops.(1) DISCUSSION: In phase 3 clinical trials, constipation was the most commonly reported adverse reaction (8%). Approximately 50% of constipation events occurred within the first 2 weeks of treatment while the majority occurred within the first 3 months of therapy. Rates of severe constipation were less than 1% in patients receiving eluxadoline doses of 75 mg and 100 mg.(1) |
VIBERZI |
| Tricyclic; Tetracyclic Agents; Carbamazepine/Linezolid SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Linezolid is a weak, reversible inhibitor of monoamine oxidase.(1) Tricyclic and tetracyclic compounds may sensitize post-synaptic receptors to amines that are accumulating extraneuronally as a result of MAO inhibition.(2) Carbamazepine is structurally related to the tricyclic antidepressants.(3) Similarity between cyclobenzaprine and tricyclics warrants consideration of tricyclic interactions for cyclobenzaprine.(4) Mirtazapine, a tetracyclic antidepressant, should also be considered for this interaction.(5) CLINICAL EFFECTS: Concurrent use with linezolid may result in a severe reaction including hyperpyrexia, convulsions, excitability, fluctuations in blood pressure, convulsions, grand mal seizures, serotonin syndrome, coma, and death.(1) Symptoms of serotonin syndrome may include tremor, agitation, diaphoresis, hyperreflexia, clonus, tachycardia, hyperthermia, and muscle rigidity.(6) PREDISPOSING FACTORS: High doses of tricyclics or tetracyclics, or concurrent use of multiple drugs which increase CNS serotonin levels may increase risk for serotonin syndrome. PATIENT MANAGEMENT: The manufacturers of the tricyclic antidepressants, carbamazepine, cyclobenzaprine and mirtazapine state that coadministration with MAO inhibitors is contraindicated. Concurrent linezolid is specifically contraindicated by the manufacturers of clomipramine, desipramine, mirtazapine, nortriptyline, and trimipramine.(1,3-5,7-12) The manufacturer of linezolid does not contraindicate the use of serotonergic agents but states that they should not be coadministered unless clinically appropriate and the patient is closely monitored.(1) This recommendation is consistent with the 2011 FDA Drug Safety Communication on linezolid and serotonergic psychiatric medications.(13,14) In non-emergency situations in patients maintained on tricyclics or tetracyclics when linezolid therapy is planned, discontinue the patient's tricyclic or tetracyclic at least 2 weeks in advance of linezolid therapy. In emergency situations in patients maintained on tricyclics or tetracyclics, weigh the availability and safety of alternatives to linezolid against the risk of serotonin syndrome. If linezolid therapy is required, the patient's tricyclic or tetracyclic should be immediately discontinued. Patients should be monitored for serotonin syndrome for 2 weeks or until 24 hours after the last dose of linezolid, whichever comes first. The patient's tricyclic or tetracyclic therapy may be resumed 24 hours after the last dose of linezolid.(13) Clinical studies have found a low incidence of serotonin syndrome in patients on concomitant linezolid and serotonergic agents, ranging from 0.24% to 4%, depending on the quality and size of the study. While linezolid-associated serotonin syndrome is potentially serious and fatal, if treated early, it is quickly reversible with discontinuation of offending agents and supportive care. Therefore, some authors suggest that use of serotonergic medications should not preclude the use of linezolid but that the clinical situation should be assessed. If concurrent use or use of linezolid without a washout is warranted, the patient should be closely monitored.(15-20) If concurrent therapy is warranted, patients should be monitored for signs and symptoms of serotonin syndrome. Instruct patients to report muscle twitching, tremors, shivering and stiffness, fever, heavy sweating, heart palpitations, restlessness, confusion, agitation, trouble with coordination, or severe diarrhea. DISCUSSION: It should be noted that if this interaction occurs, the consequences will be immediate and severe. Effects may continue to be seen for several days after discontinuing linezolid. The FDA FAERS contains reports of serotonin syndrome with the concurrent use of linezolid and citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine. The risk of serotonin syndrome with other psychiatric drugs is unclear.(14) |
LINEZOLID, LINEZOLID-0.9% NACL, LINEZOLID-D5W, ZYVOX |
| Tramadol/Tricyclic Compounds; Carbamazepine SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Tramadol and tricyclic compounds may lower the seizure threshold.(1) Tramadol inhibits the reuptake of serotonin and norepinephrine but has weak opioid effects. M1, tramadol's active metabolite, is a stronger opioid and up to 6 times more potent than tramadol in producing analgesia.(1) Carbamazepine induces the metabolism of this tramadol opioid metabolite. CLINICAL EFFECTS: Concurrent use of tramadol and a tricyclic compound may result in seizures or serotonin syndrome and may increase the risk of suicide.(1) Concurrent use of tramadol and carbamazepine may significantly reduce the analgesic effect of tramadol.(1) Although not used therapeutically as an antidepressant, carbamazepine is a tricyclic compound. PREDISPOSING FACTORS: Risk of seizures may be increased in patients with epilepsy, a history of seizures, head trauma, metabolic disorders, alcohol or drug withdrawal, or infections of the central nervous system.(1) PATIENT MANAGEMENT: Tramadol should be used with caution in patients taking tricyclic compounds.(1) The use of tramadol and carbamazepine is not recommended.(1) Carbamazepine induces metabolism (glucuronidation) of the tramadol opioid metabolite (M1). In patients on long-term carbamazepine when tramadol is started, achieving adequate analgesia may be difficult. Prescribing higher tramadol doses would be associated with higher parent drug levels which may result in serotonin and norepinephrine associated adverse effects. In patients receiving chronic tramadol treatment when carbamazepine is started, anticipate a reduction in analgesic effects. The maximal effects of carbamazepine on tramadol efficacy may not be seen for 2 or more weeks. Monitor for decreased tramadol efficacy, including symptoms of opioid withdrawal, after carbamazepine is initiated or when carbamazepine dosage is increased. If carbamazepine is to be discontinued in patients stabilized on the combination of tramadol and carbamazepine, gradually decrease the carbamazepine dose to decrease the risk of withdrawal seizures. As carbamazepine induction wanes, systemic tramadol metabolite concentrations will rise. The tramadol dose may need to be decreased to prevent tramadol toxicity. DISCUSSION: The use of tramadol in patients treated with tricyclic compounds may increase the risk of seizures.(1) A review of 124 reports of seizures following tramadol therapy received by the FDA through July 31, 1996 revealed that 23% of the patients were also taking tricyclic antidepressants.(2) Therefore, the manufacturer of tramadol states that tramadol should be used with caution in patients treated with tricyclic compounds.(1) The manufacturer of tramadol also states that the use of tramadol with carbamazepine is not recommended.(1) In a case report, a 79 year-old female developed serotonin syndrome three days after the addition of tramadol to amitriptyline therapy. Over the next four days, her condition deteriorated and she died.(3) |
CONZIP, QDOLO, TRAMADOL HCL, TRAMADOL HCL ER, TRAMADOL HCL-ACETAMINOPHEN |
| Glucagon (Diagnostic)/Anticholinergics SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Glucagon and anticholinergic agents may have additive effects on inhibition of gastrointestinal motility.(1) CLINICAL EFFECTS: Concurrent use of glucagon with anticholinergic agents may increase the risk of gastrointestinal hypomotility, including constipation and bowel complications.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Concurrent use of glucagon as a diagnotic aid is not recommended with the use of anticholinergic agents.(1) If concurrent use is necessary, evaluate the patient's bowel function. Monitor for symptoms of constipation and gastrointestinal hypomotility. DISCUSSION: Both glucagon and anticholinergic agents may have additive effects on inhibition of gastrointestinal motility and increase the risk of gastrointestinal adverse effects.(1) |
GLUCAGON HCL |
There are 15 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Clonidine/Tricyclic Compounds; Mirtazapine SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Clonidine decreases blood pressure via alpha-2 agonism.(1) Tricyclic compounds(2) and mirtazapine(3) antagonize alpha-2, which may result in a loss of effect of clonidine. CLINICAL EFFECTS: The concurrent use of clonidine and tricyclic compounds(1,3,4-16) and mirtazapine(3,17) may result in decreased effectiveness of clonidine and hypertensive crisis. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: If possible, avoid concurrent use of clonidine with tricyclic compounds or mirtazapine. Consider using an alternative agent in patients maintained on clonidine. If concurrent administration is warranted, blood pressure should be carefully monitored, particularly in the first two weeks of therapy, when this interaction is most likely to occur. The dosage of clonidine may need to be adjusted or the tricyclic compound or mirtazapine may need to be discontinued. DISCUSSION: This interaction has been reported in patients receiving amitriptyline,(6) clomipramine,(7,8) desipramine,(2,9-11) imipramine(12-16), and protriptyline.(11) In one patient, a hypertensive crisis resulted. Other patients experienced a decrease in blood pressure control. A controlled trial demonstrated a decrease in anti-hypertensive effect when desipramine was added to a clonidine regimen. This decrease in hypertensive-control may be overcome by increasing the dose of clonidine and monitoring blood pressure closely. Cyclobenzaprine is structurally related to the tricyclic antidepressants and, especially at higher dosages, has similar effects.(18) Therefore, it is prudent to consider cyclobenzaprine in this interaction. Hypertensive crisis has been reported during concurrent clonidine and mirtazapine therapy.(3,17) Mianserin(19,20) and maprotiline,(21) tetracyclic antidepressants, have been shown not to affect the antihypertensive effects of clonidine. |
CATAPRES-TTS 1, CATAPRES-TTS 2, CATAPRES-TTS 3, CLONIDINE, CLONIDINE HCL, CLONIDINE HCL ER, DURACLON, NEXICLON XR, ONYDA XR, R.E.C.K.(ROPIV-EPI-CLON-KETOR), ROPIVACAINE-CLONIDINE-KETOROLC |
| Duloxetine; Fluvoxamine/Selected Tricyclic Compounds SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Duloxetine or fluvoxamine may impair the oxidative hepatic metabolism of tricyclic compounds. CLINICAL EFFECTS: Concurrent administration of duloxetine or fluvoxamine with a tricyclic compound may result in an increase in serum levels, toxicities (e.g. torsades de pointes), and/or clinical effects of the tricyclic compound. PREDISPOSING FACTORS: The risk of seizures may be increased in patients with a history of head trauma or prior seizure; CNS tumor; severe hepatic cirrhosis; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; use of over-the-counter stimulants and anorectics; diabetics treated with oral hypoglycemics or insulin; or with concomitant medications known to lower seizure threshold (antipsychotics, theophylline, systemic steroids). The risk of anticholinergic toxicities including cognitive decline, delirium, falls and fractures is increased in geriatric patients using more than one medicine with anticholinergic properties.(9) PATIENT MANAGEMENT: Patients should be observed for increased adverse effects and clinical effects of tricyclic compounds at the initiation of concurrent therapy with duloxetine or fluvoxamine. Plasma concentrations of the tricyclic compound should be monitored and the dosage adjusted accordingly. If duloxetine or fluvoxamine is discontinued in a patient receiving a tricyclic compound, the dosage of the tricyclic compound may need to be adjusted. DISCUSSION: In a study, pretreatment with duloxetine (60 mg twice daily) increased the area-under-curve (AUC) of a single dose of desipramine (50 mg) by 3-fold. Fluvoxamine has been shown in an in vitro study to inhibit the metabolism of imipramine. Three case reports have shown increased serum levels of imipramine (32%, 198%, and 470% increases) and an increase in adverse effects (anticholinergic effects, confusion, and sedation) during concurrent administration with fluvoxamine. Two case reports of adverse effects (tonic-clonic seizure, tremors, dizziness, and confusion) and increased plasma desipramine levels (79% and 54% increases) with concurrent administration of fluvoxamine exist. Increased plasma levels of clomipramine (586%) and amitriptyline (100-150%) without signs of clinical toxicity were seen following the addition of fluvoxamine to a tricyclic compound therapy. The affinity of the different SSRIs, SNRIs, and tricyclics for CYP450 may vary. |
CYMBALTA, DRIZALMA SPRINKLE, DULOXETINE HCL, DULOXICAINE, FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE ER |
| Tricyclic Compounds/Cimetidine SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Cimetidine inhibits the hepatic metabolism of tricyclic antidepressants. CLINICAL EFFECTS: The pharmacological and toxic effects of tricyclic antidepressants may be increased. PREDISPOSING FACTORS: The risk of seizures may be increased in patients with a history of head trauma or prior seizure; CNS tumor; severe hepatic cirrhosis; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; use of over-the-counter stimulants and anorectics; diabetics treated with oral hypoglycemics or insulin; or with concomitant medications known to lower seizure threshold (antipsychotics, theophylline, systemic steroids). The risk of anticholinergic toxicities including cognitive decline, delirium, falls and fractures is increased in geriatric patients using more than one medicine with anticholinergic properties.(9) PATIENT MANAGEMENT: Observe the patient for an increased or decreased response to tricyclic antidepressant therapy if cimetidine is started or stopped. Adjust the dose of the tricyclic agent accordingly. This interaction can probably be avoided by administration of an H-2 receptor antagonist other than cimetidine (e.g., famotidine, nizatidine, ranitidine). DISCUSSION: Both controlled studies and case reports have demonstrated that concurrent administration of tricyclic antidepressants and cimetidine can result in an increase in plasma tricyclic antidepressant concentrations. Adverse effects have been reported. Similarity between cyclobenzaprine and TCA's warrants consideration of TCA interactions for cyclobenzaprine. |
CIMETIDINE |
| Tricyclic Compounds/Fosamprenavir; Tipranavir SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Fosamprenavir and tipranavir may inhibit the metabolism of tricyclic compounds.(1,2) CLINICAL EFFECTS: Concurrent use of fosamprenavir(1) or tipranavir(2) with tricyclic compounds may result in elevated levels of the tricyclic agents and serious and/or life-threatening effects. PREDISPOSING FACTORS: The risk of seizures may be increased in patients with a history of head trauma or prior seizure; CNS tumor; severe hepatic cirrhosis; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; use of over-the-counter stimulants and anorectics; diabetics treated with oral hypoglycemics or insulin; or with concomitant medications known to lower seizure threshold (antipsychotics, theophylline, systemic steroids). The risk of anticholinergic toxicities including cognitive decline, delirium, falls and fractures is increased in geriatric patients using more than one medicine with anticholinergic properties.(4) PATIENT MANAGEMENT: The manufacturer of fosamprenavir(1) recommends caution with concurrent use of these agents with tricyclic compounds, along with concentration monitoring of the tricyclics. The manufacturer of tipranavir recommends dosage reduction and concentration monitoring of desipramine when coadministered with tipranavir/ritonavir.(2) DISCUSSION: Amprenavir has been shown to be a potent inhibitor of CYP3A4.(1,3) Fosamprenavir is a prodrug of amprenavir.(1) Therefore, the manufacturer of amprenavir(3) and fosamprenavir(1) recommends caution with concurrent use of these agents with tricyclic compounds, along with concentration monitoring of the tricyclic compounds. No interaction studies have been performed on the combination of tipranavir-ritonavir and desipramine. Desipramine is a sensitive substrate of CYP2D6 while tipranavir-ritonavir is a moderate CYP2D6 inhibitor.(5,6) In one clinical study, six subjects were given 50 mg desipramine on three occasions: alone, after a 60 mg dose of fluoxetine (strong CYP2D6 inhibitor), and after eight daily 60 mg doses of fluoxetine. Fluoxetine significantly reduced oral clearance of desipramine by up to 10-fold and prolonged the half-life of desipramine by up to 4-fold.(7) |
APTIVUS, FOSAMPRENAVIR CALCIUM |
| Tricyclic Compounds/Terbinafine SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Terbinafine may inhibit the metabolism of tricyclic compounds by CYP2D6.(1-5) CLINICAL EFFECTS: Concurrent use of terbinafine may result in elevated levels of and toxicity from the tricyclic agent. PREDISPOSING FACTORS: The risk of seizures may be increased in patients with a history of head trauma or prior seizure; CNS tumor; severe hepatic cirrhosis; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; use of over-the-counter stimulants and anorectics; diabetics treated with oral hypoglycemics or insulin; or with concomitant medications known to lower seizure threshold (antipsychotics, theophylline, systemic steroids). The risk of anticholinergic toxicities including cognitive decline, delirium, falls and fractures is increased in geriatric patients using more than one medicine with anticholinergic properties.(6) PATIENT MANAGEMENT: Monitor tricyclic levels in patients receiving concurrent therapy with terbinafine. The dose of the tricyclic agent may need to be adjusted if terbinafine is initiated or discontinued. The effect of terbinafine on tricyclics may last for up to four weeks after terbinafine discontinuation. DISCUSSION: In a study in 12 healthy subjects, a single dose of desipramine (50 mg) was given alone, after 21 days of terbinafine (250 mg daily), and 2 and 4 weeks after discontinuation of terbinafine. Administration after 21 days of terbinafine therapy increased the area-under-curve (AUC) and maximum concentration (Cmax) of desipramine by 5-fold and 2-fold, respectively. The AUC and Cmax of desipramine were still elevated when desipramine was administered 4 weeks after the completion of terbinafine therapy.(1,2) There are case reports of toxicity during concurrent terbinafine and desipramine,(3) imipramine,(4) and nortriptyline.(5,7-8) In the UK manufacturer states that terbinafine decreased the clearance of desipramine by 82%.(9) |
TERBINAFINE HCL |
| Lower Strength Tricyclics; Trazodone/Fluoxetine; Paroxetine SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Depending upon the interacting combination, pharmacokinetic and/or pharmacodynamic interactions are possible. Fluoxetine is a moderate inhibitor of CYP2C19 and a strong inhibitor of CYP2D6.(1) Paroxetine is a strong inhibitor of CYP2D6.(1,2) Amitriptyline, clomipramine, doxepin, imipramine and trimipramine are metabolized by CYP2C19 and CYP2D6.(1) Desipramine, nortriptyline, amoxapine, and protriptyline are metabolized by CYP2D6.(1) Trazodone is metabolized to mCPP, an active metabolite with potential adverse effects, by CYP2D6. Cyclobenzaprine is metabolized by CYP1A2 and CYP3A4 and so a pharmacokinetic interaction is not expected. Fluoxetine, paroxetine, and clomipramine significantly increase neuronal serotonin levels. CLINICAL EFFECTS: Concurrent administration of fluoxetine or paroxetine with tricyclics metabolized by CYP2D6 or CYP2C19 may result in an increase in serum levels, toxicities (e.g. risk for seizures, severe anticholinergic effects), and/or clinical effects of the tricyclic or trazodone. Elevated levels of tricyclics and trazodone may increase the risk of QT prolongation and the risk for torsades de pointes. Concurrent administration of fluoxetine or paroxetine with clomipramine and perhaps with imipramine, cyclobenzaprine, high dose amitriptyline, or trazodone may increase the risk for serotonin syndrome. PREDISPOSING FACTORS: Higher doses or higher systemic concentrations of fluoxetine or paroxetine may increase the magnitude of this interaction. The risk of QT prolongation or torsades de pointes may be increased in patients with cardiovascular disease (e.g. heart failure, myocardial infarction, history of torsades de pointes, congenital long QT syndrome), hypokalemia, hypomagnesemia, hypocalcemia, bradycardia, female gender, or advanced age.(19) Concurrent use of more than one drug known to cause QT prolongation or higher systemic concentrations of either QT prolonging drug are additional risk factors for torsades de pointes. Factors which may increase systemic drug concentrations include rapid infusion of an intravenous dose or impaired metabolism or elimination of the drug (e.g. coadministration with an agent which inhibitors its metabolism or elimination, genetic impairment in drug metabolism or elimination, and/or renal/hepatic dysfunction).(19) Concurrent use of multiple drugs which increase CNS serotonin levels would be expected to further increase risk for serotonin syndrome.(20) The risk of seizures may be increased in patients with a history of head trauma or prior seizure; CNS tumor; severe hepatic cirrhosis; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; use of over-the-counter stimulants and anorectics; diabetics treated with oral hypoglycemics or insulin; or with concomitant medications known to lower seizure threshold (antipsychotics, theophylline, systemic steroids). The risk of anticholinergic toxicities including cognitive decline, delirium, falls and fractures is increased in geriatric patients using more than one medicine with anticholinergic properties.(21) PATIENT MANAGEMENT: Patients should be observed for increased adverse effects and clinical effects of tricyclic compounds or trazodone when concurrent therapy with fluoxetine or paroxetine is started or if the dosage of either agent is increased. Plasma concentrations of the tricyclic compound (e.g. amitriptyline/nortriptyline, imipramine/desipramine) should be monitored and the dosage adjusted accordingly. If the fluoxetine or paroxetine is discontinued in a patient receiving a trazodone or tricyclic compound other than cyclobenzaprine, the dosage may need to be adjusted upward as the effects of enzyme inhibition wane. The effects of fluoxetine on hepatic metabolism may last for 3-5 weeks after fluoxetine discontinuation. A cyclic compound (other than cyclobenzaprine) started after the discontinuation of fluoxetine should be started at a lower initial dosage. Patients receiving fluoxetine or paroxetine and clomipramine, imipramine, and perhaps cyclobenzaprine, higher dose amitriptyline, or trazodone should be monitored for serotonin syndrome. Mild serotonin symptoms may include: shivering, diaphoresis, mydriasis, intermittent tremor, and/or myoclonus. Moderate serotonin symptoms may include: tachycardia, hypertension, hyperthermia, mydriasis, diaphoresis, hyperactive bowel sounds, hyperreflexia, and/OR clonus. Severe serotonin symptoms may include: severe hypertension and tachycardia, shock, agitated delirium, muscular rigidity, and/or hypertonicity.(20) When concurrent therapy may be associated with QT prolongation, consider obtaining serum calcium, magnesium, and potassium levels and monitoring ECG at baseline and at regular intervals. Correct any electrolyte abnormalities. Instruct patients to report any irregular heartbeat, dizziness, or fainting. DISCUSSION: Case reports have shown that the addition of fluoxetine to a tricyclic compound therapy can result in an increase of 100-300% in the tricyclic compound plasma concentration as well as an increase in adverse effects, including seizures and delirium. In a 83 year-old patient, the combination of clomipramine and fluoxetine resulted in high clomipramine concentrations and cardiac side effects. In a 70 year old patient, the use of venlafaxine, fluoxetine, and nortriptyline was associated with severe anticholinergic side effects. This interaction was thought to be due to increased nortriptyline levels. There is one case report of serotonin syndrome during concurrent therapy with paroxetine and trazodone.(24) There have also been case reports of serotonin syndrome with trazodone and fluoxetine,(28) and trazodone and amitriptyline with lithium. In a 24 year-old patient, the use of fluoxetine and trazodone resulted in severe irritability, anger, anxiety, and anorexia.(25) In a study in 11 patients, concurrent administration of trazodone 100 mg/day and fluoxetine 20 mg/day increased the concentrations of trazodone and its active metabolite mCPP by 65% and 231%.(27) In a 50 year-old patient, the use of protriptyline and fluoxetine resulted in anticholinergic delirium.(26) The manufacturer of cyclobenzaprine reports that serotonin syndrome has been reported when combined with other serotonergic agents.(23) QTc prolongation also exists with some antidepressants. In a case report, the combination of levofloxacin, imipramine, and fluoxetine was associated with a QTc of 509msec. The authors concluded that this interaction was due to the pharmacodynamic additive effect among fluoxetine, imipramine, and levofloxacin. Cyclic agents included in this monograph are amitriptyline (<=40mg), amoxapine, clomipramine (<=25mg), cyclobenzaprine (structurally similar to amitriptyline), doxepin (<=25mg), imipramine (<=10mg), melitracen, nortriptyline (<=30mg), protriptyline, trazodone (<=75mg), and trimipramine (<=25mg). |
FLUOXETINE DR, FLUOXETINE HCL, OLANZAPINE-FLUOXETINE HCL, PAROXETINE CR, PAROXETINE ER, PAROXETINE HCL, PAROXETINE MESYLATE, PAXIL, PAXIL CR, PROZAC |
| Inhaled Direct-Acting Sympathomimetics/Tricyclic Compounds SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Unknown. However, it is speculated that direct-acting sympathomimetic amines have an enhanced effect due to tricyclic blockage of norepinephrine reuptake. CLINICAL EFFECTS: Increased effect of direct acting sympathomimetics. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The concurrent use of inhaled sympathomimetics and tricyclic compounds or the use of these agents within 14 days of each other should be approached with extreme caution. DISCUSSION: Epinephrine and other direct-acting sympathomimetic amines exert enhanced cardiovascular effects (e.g., arrhythmias, hypertension, and tachycardia) in individuals concurrently receiving or previously treated with tricyclic antidepressants. Protriptyline, amitriptyline, and desipramine have also been reported to interact with direct-acting sympathomimetics. Similarity between cyclobenzaprine and the tricyclic antidepressants consideration of tricyclic antidepressant interactions for cyclobenzaprine. |
ADVAIR DISKUS, ADVAIR HFA, AIRDUO DIGIHALER, AIRDUO RESPICLICK, AIRSUPRA, ALBUTEROL SULFATE, ALBUTEROL SULFATE HFA, ANORO ELLIPTA, ARFORMOTEROL TARTRATE, BEVESPI AEROSPHERE, BREO ELLIPTA, BREYNA, BREZTRI AEROSPHERE, BROVANA, BUDESONIDE-FORMOTEROL FUMARATE, COMBIVENT RESPIMAT, DUAKLIR PRESSAIR, DULERA, FLUTICASONE-SALMETEROL, FLUTICASONE-SALMETEROL HFA, FLUTICASONE-VILANTEROL, FORMOTEROL FUMARATE, IPRATROPIUM-ALBUTEROL, LEVALBUTEROL CONCENTRATE, LEVALBUTEROL HCL, LEVALBUTEROL TARTRATE HFA, PERFOROMIST, PROAIR DIGIHALER, PROAIR RESPICLICK, SEREVENT DISKUS, STIOLTO RESPIMAT, STRIVERDI RESPIMAT, SYMBICORT, TRELEGY ELLIPTA, UMECLIDINIUM-VILANTEROL, VENTOLIN HFA, WIXELA INHUB, XOPENEX HFA |
| Desmopressin/Agents with Hyponatremia Risk SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Carbamazepine, chlorpromazine, lamotrigine, NSAIDs, opioids, SSRIs, thiazide diuretics, and/or tricyclic antidepressants increase the risk of hyponatremia.(1-3) CLINICAL EFFECTS: Concurrent use may increase the risk of hyponatremia with desmopressin.(1-3) PREDISPOSING FACTORS: Predisposing factors for hyponatremia include: polydipsia, renal impairment (eGFR < 50 ml/min/1.73m2), illnesses that can cause fluid/electrolyte imbalances, age >=65, medications that cause water retention and/or increase the risk of hyponatremia (glucocorticoids, loop diuretics). PATIENT MANAGEMENT: The concurrent use of agents with a risk of hyponatremia with desmopressin may increase the risk of hyponatremia. If concurrent use is deemed medically necessary, make sure serum sodium levels are normal before beginning therapy and consider using the desmopressin nasal 0.83 mcg dose. Consider measuring serum sodium levels more frequently than the recommended intervals of: within 7 days of concurrent therapy initiation, one month after concurrent therapy initiation and periodically during treatment. Counsel patients to report symptoms of hyponatremia, which may include: headache, nausea/vomiting, feeling restless, fatigue, drowsiness, dizziness, muscle cramps, changes in mental state (confusion, decreased awareness/alertness), seizures, coma, and trouble breathing. Counsel patients to limit the amount of fluids they drink in the evening and night-time and to stop taking desmopressin if they develop a stomach/intestinal virus with nausea/vomiting or any nose problems (blockage, stuffy/runny nose, drainage).(1) DISCUSSION: In clinical trials of desmopressin for the treatment of nocturia, 4 of 5 patients who developed severe hyponatremia (serum sodium <= 125 mmol/L) were taking systemic or inhaled glucocorticoids. Three of these patients were also taking NSAIDs and one was receiving a thiazide diuretic.(2) Drugs associated with hyponatremia may increase the risk, including loop diuretics, carbamazepine, chlorpromazine, glucocorticoids, lamotrigine, NSAIDs, opioids, SSRIs, thiazide diuretics, and/or tricyclic antidepressants.(1,3-4) |
DDAVP, DESMOPRESSIN ACETATE, NOCDURNA |
| Sertraline (Less Than or Equal To 50 mg)/Select Tricyclic Compounds; Trazodone SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Depending upon the interacting combination, pharmacokinetic and/or pharmacodynamic interactions are possible. Sertraline, a SSRI, may impair the oxidative hepatic metabolism of tricyclic compounds and trazodone. CLINICAL EFFECTS: Concurrent administration of sertraline, an SSRI, with a tricyclic compound or trazodone may result in an increase in serum levels, toxicities (e.g. torsades de pointes and/or serotonin syndrome), and/or clinical effects of the tricyclic compound or trazodone PREDISPOSING FACTORS: The risk of QT prolongation or torsades de pointes may be increased in patients with cardiovascular disease (e.g. heart failure, myocardial infarction, history of torsades de pointes, congenital long QT syndrome), hypokalemia, hypomagnesemia, hypocalcemia, bradycardia, female gender, or advanced age.(8) Concurrent use of more than one drug known to cause QT prolongation or higher systemic concentrations of either QT prolonging drug are additional risk factors for torsades de pointes. Factors which may increase systemic drug concentrations include rapid infusion of an intravenous dose or impaired metabolism or elimination of the drug (e.g. coadministration with an agent which inhibitors its metabolism or elimination, genetic impairment in drug metabolism or elimination, and/or renal/hepatic dysfunction).(8) The risk of seizures may be increased in patients with a history of head trauma or prior seizure; CNS tumor; severe hepatic cirrhosis; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; use of over-the-counter stimulants and anorectics; diabetics treated with oral hypoglycemics or insulin; or with concomitant medications known to lower seizure threshold (antipsychotics, theophylline, systemic steroids). The risk of anticholinergic toxicities including cognitive decline, delirium, falls and fractures is increased in geriatric patients using more than one medicine with anticholinergic properties.(10) PATIENT MANAGEMENT: Patients should be observed for increased adverse effects and clinical effects of tricyclic compounds at the initiation of concurrent therapy with sertraline, an SSRI. Plasma concentrations of the tricyclic compound should be monitored and the dosage adjusted accordingly. If sertraline is discontinued in a patient receiving a tricyclic compound, the dosage of the tricyclic compound may need to be adjusted. If concurrent therapy is warranted, consider obtaining serum calcium, magnesium, and potassium levels and monitoring ECG at baseline and at regular intervals. Correct any electrolyte abnormalities. Instruct patients to report any irregular heartbeat, dizziness, or fainting. Patients receiving concurrent therapy with sertraline and clomipramine, imipramine, and/or trazodone should be monitored for serotonin syndrome. Mild serotonin symptoms may include: shivering, diaphoresis, mydriasis, intermittent tremor, and/or myoclonus. Moderate serotonin symptoms may include: tachycardia, hypertension, hyperthermia, mydriasis, diaphoresis, hyperactive bowel sounds, hyperreflexia, and/OR clonus. Severe serotonin symptoms may include: severe hypertension and tachycardia, shock, agitated delirium, muscular rigidity, and/or hypertonicity. DISCUSSION: Sertraline has been shown to increase the maximum concentration (Cmax) and AUC of desipramine by 31% and 23%, respectively. The affinity of the different SSRIs, SNRIs, and tricyclics for CYP450 may vary. |
SERTRALINE HCL, ZOLOFT |
| Bupropion/Tricyclic Antidepressants SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Depending upon the antidepressant, one or two mechanisms may be involved. Both bupropion and tricyclic antidepressants are known to lower the seizure threshold.(1,2) Bupropion, a strong inhibitor of CYP2D6, may increase systemic exposure (AUC, area-under-curve) to tricyclic antidepressants that are metabolized by this pathway. Antidepressants which are very sensitive to CYP2D6 inhibition are: desipramine, doxepin, and trimipramine. Antidepressants which are moderately sensitive to CYP2D6 inhibition are: amitriptyline, imipramine, maprotiline, and nortriptyline. Antidepressants which are metabolized by CYP2D6 but less susceptible to CYP2D6 inhibition includes clomipramine.(3) CLINICAL EFFECTS: Concurrent use of bupropion and a tricyclic antidepressant may result in additive effects on the seizure threshold, increasing the risk of seizures.(1,2) Concurrent use may also increase levels of and side effects from antidepressants metabolized by CYP2D6, such as amitriptyline, clomipramine, imipramine, maprotiline, and nortriptyline.(3) PREDISPOSING FACTORS: The risk of seizures may be increased in patients with a history of head trauma or prior seizure; CNS tumor; severe hepatic cirrhosis; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; use of over-the-counter stimulants and anorectics; a total daily dose of bupropion greater than 450 mg or single doses greater than 150 mg; rapid escalation of bupropion dosage; diabetics treated with oral hypoglycemics or insulin; or with concomitant medications known to lower seizure threshold (antipsychotics, theophylline, systemic steroids).(1,2) The risk of anticholinergic toxicities including cognitive decline, delirium, falls and fractures is increased in geriatric patients using more than one medicine with anticholinergic properties.(4) PATIENT MANAGEMENT: The concurrent use of bupropion and tricyclic antidepressants should be undertaken only with extreme caution and with low initial bupropion dosing and small gradual dosage increases.(1,2) Single doses should not exceed 150 mg.(1,2) The maximum daily dose of bupropion should not exceed 300 mg for smoking cessation(2) or 450 mg for depression.(1) DISCUSSION: Because of the risk of seizure from concurrent bupropion and other agents that lower seizure threshold, the manufacturer of bupropion states that the concurrent use of bupropion and antidepressants should be undertaken only with extreme caution and with low initial bupropion dosing and small gradual dosage increases.(1,2) In a study in 15 male subjects who were extensive metabolizers of CYP2D6, bupropion (150 mg twice daily) increased the maximum concentration (Cmax), area-under-curve (AUC), and half-life (T1/2) of a single dose of desipramine (50 mg) by 2-fold, 5-fold, and 2-fold, respectively.(1,2) |
APLENZIN, AUVELITY, BUPROPION HCL, BUPROPION HCL SR, BUPROPION XL, CONTRAVE, FORFIVO XL, WELLBUTRIN SR, WELLBUTRIN XL |
| Desvenlafaxine; Venlafaxine/Selected Tricyclic Compounds SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Desvenlafaxine or venlafaxine may impair the oxidative hepatic metabolism of tricyclic compounds via CYP2D6. CLINICAL EFFECTS: Concurrent administration of desvenlafaxine or venlafaxine with a tricyclic compound may result in an increase in serum levels, toxicities, and/or clinical effects of the tricyclic compound. PREDISPOSING FACTORS: The risk of seizures may be increased in patients with a history of head trauma or prior seizure; CNS tumor; severe hepatic cirrhosis; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; use of over-the-counter stimulants and anorectics; diabetics treated with oral hypoglycemics or insulin; or with concomitant medications known to lower seizure threshold (antipsychotics, theophylline, systemic steroids). The risk of anticholinergic toxicities including cognitive decline, delirium, falls and fractures is increased in geriatric patients using more than one medicine with anticholinergic properties.(5) PATIENT MANAGEMENT: Patients should be observed for increased adverse effects and clinical effects of tricyclic compounds at the initiation of concurrent therapy with desvenlafaxine or venlafaxine. Plasma concentrations of the tricyclic compound should be monitored and the dosage adjusted accordingly. If desvenlafaxine or venlafaxine is discontinued in a patient receiving a tricyclic compound, the dosage of the tricyclic compound may need to be adjusted. The US manufacturer of desvenlafaxine recommends the dose of desipramine be reduced by up to one-half when administered with desvenlafaxine 400 mg. DISCUSSION: In a 70 year old patient, the use of venlafaxine, fluoxetine, and nortriptyline was associated with severe anticholinergic side effects. This interaction was thought to be due to increased nortriptyline levels. A case report of anticholinergic toxic syndrome with venlafaxine and desipramine combination exist as well. Concomitant administration of desvenlafaxine 400 mg with a single 50 mg dose of desipramine resulted in an increase in the Cmax and AUC of desipramine by approximately 50% and 90%. The affinity of the different SSRIs, SNRIs, and tricyclics for CYP P-450 may vary. |
DESVENLAFAXINE ER, DESVENLAFAXINE SUCCINATE ER, EFFEXOR XR, PRISTIQ, VENLAFAXINE BESYLATE ER, VENLAFAXINE HCL, VENLAFAXINE HCL ER |
| Sertraline (Greater Than 50 mg)/Selected Tricyclic Compounds SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Sertraline may impair the oxidative hepatic metabolism of tricyclic compounds. CLINICAL EFFECTS: Concurrent administration of sertraline with a tricyclic compound may result in an increase in serum levels, toxicities, and/or clinical effects of the tricyclic compound. PREDISPOSING FACTORS: The risk of seizures may be increased in patients with a history of head trauma or prior seizure; CNS tumor; severe hepatic cirrhosis; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; use of over-the-counter stimulants and anorectics; diabetics treated with oral hypoglycemics or insulin; or with concomitant medications known to lower seizure threshold (antipsychotics, theophylline, systemic steroids). The risk of anticholinergic toxicities including cognitive decline, delirium, falls and fractures is increased in geriatric patients using more than one medicine with anticholinergic properties.(8) PATIENT MANAGEMENT: Patients should be observed for increased adverse effects and clinical effects of tricyclic compounds at the initiation of concurrent therapy with sertraline. Plasma concentrations of the tricyclic compound should be monitored and the dosage adjusted accordingly. If sertraline is discontinued in a patient receiving a tricyclic compound, the dosage of the tricyclic compound may need to be adjusted. DISCUSSION: Sertraline has been shown to increase the maximum concentration (Cmax) and AUC of desipramine by 31% and 23%, respectively.(5) The affinity of the different SSRIs, SNRIs, and tricyclics for CYP P-450 may vary. |
SERTRALINE HCL, ZOLOFT |
| Zonisamide/Anticholinergics SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Zonisamide can cause decreased sweating and elevated body temperature. Agents with anticholinergic activity can predispose patients to heat-related disorders.(1-2) CLINICAL EFFECTS: Concurrent use of zonisamide with agents with anticholinergic activity may increase the incidence of oligohidrosis and hyperthermia, especially in pediatric or adolescent patients.(1-2) Overheating and dehydration can lead to brain damage and death. PREDISPOSING FACTORS: Pediatric and adolescent patients and patients with dehydration may be more likely to experience heat-related disorders.(1) PATIENT MANAGEMENT: The UK and US manufacturers of zonisamide state that caution should be used in adults when zonisamide is prescribed with other medicinal products that predispose to heat-related disorders, such as agents with anticholinergic activity.(1-2) Pediatric and adolescent patients must not take anticholinergic agents (e.g. clomipramine, hydroxyzine, diphenhydramine, haloperidol, imipramine, and oxybutynin) concurrently with zonisamide.(1) Monitor for signs and symptoms of heat stroke: skin feels very hot with little or no sweating, confusion, muscle cramps, rapid heartbeat, or rapid breathing. Monitor for signs and symptoms of dehydration: dry mouth, urinating less than usual, dark-colored urine, dry skin, feeling tired, dizziness, or irritability. If signs or symptoms of dehydration, oligohidrosis, or elevated body temperature occur, discontinuation of zonisamide should be considered. DISCUSSION: Case reports of decreased sweating and elevated temperature have been reported, especially in pediatric patients. Some cases resulted in heat stroke that required hospital treatment and resulted in death.(1) |
ZONEGRAN, ZONISADE, ZONISAMIDE |
| Topiramate/Anticholinergics SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Topiramate can cause decreased sweating and elevated body temperature. Agents with anticholinergic activity can predispose patients to heat-related disorders.(1-2) CLINICAL EFFECTS: Concurrent use of topiramate with agents with anticholinergic activity may increase the incidence of oligohidrosis and hyperthermia, especially in pediatric or adolescent patients.(1-2) Overheating and dehydration can lead to brain damage and death. PREDISPOSING FACTORS: Pediatric and adolescent patients and patients with dehydration may be more likely to experience heat-related disorders.(1) PATIENT MANAGEMENT: The manufacturer of topiramate states that caution should be used when topiramate is prescribed with other medicinal products that predispose to heat-related disorders, such as agents with anticholinergic activity (e.g. clomipramine, hydroxyzine, diphenhydramine, haloperidol, imipramine, and oxybutynin) concurrently with zonisamide.(1) Monitor for signs and symptoms of heat stroke: skin feels very hot with little or no sweating, confusion, muscle cramps, rapid heartbeat, or rapid breathing. Monitor for signs and symptoms of dehydration: dry mouth, urinating less than usual, dark-colored urine, dry skin, feeling tired, dizziness, or irritability. If signs or symptoms of dehydration, oligohidrosis, or elevated body temperature occur, discontinuation of zonisamide should be considered. DISCUSSION: Case reports of decreased sweating and elevated temperature have been reported, especially in pediatric patients. Some cases resulted in heat stroke that required hospital treatment.(1) A 64-year old woman developed non-exertional hyperthemia while taking multiple psychiatric medications with topiramate.(2) |
EPRONTIA, QSYMIA, TOPAMAX, TOPIRAMATE, TOPIRAMATE ER, TOPIRAMATE ER SPRINKLE, TROKENDI XR |
| Tricyclic Antidepressants; Mianserin/Carbamazepine SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Carbamazepine may induce the metabolism of tricyclic antidepressants (TCAs) and mianserin by the CYP P450 isoenzyme system.(1,2) CLINICAL EFFECTS: The concurrent administration of TCAs or mianserin with carbamazepine may result in decreased levels and clinical effects of the TCA or mianserin.(1,2) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Patients receiving both of these medications should be alerted to the possibility of decreased effects of the TCA or mianserin.(1,2) Observe the patient for loss of the therapeutic effect of the TCA or mianserin and consider monitoring TCA or mianserin levels during concurrent therapy.(3,4) Consider dose adjustment of the TCA or mianserin if carbamazepine is added to or discontinued from concurrent therapy.(2,4) DISCUSSION: A study of 22 psychiatric patients examined the effects of carbamazepine on serum levels of several antidepressants. Carbamazepine lowered amitriptyline levels by 60%, doxepin levels by 55%, and mianserin levels by 70%. The authors recommended carefully monitoring antidepressant drug levels when carbamazepine is coadministered.(3) A large retrospective study found that patients on carbamazepine with amitriptyline or nortriptyline had concentration/dose (C/D) ratios for the antidepressants that were about 50% lower than the C/D ratios for patients not on carbamazepine. The authors suggest that therapeutic drug monitoring is valuable for managing drug interactions.(4) In healthy volunteers, carbamazepine 200 mg twice daily for 28 days increased desipramine clearance by 31%.(6) In a study of 13 patients with depression, carbamazepine 400 mg per day decreased total imipramine levels by 39.5% and desipramine levels by 24.5% but levels of the pharmacologically active free drugs were not affected. The authors suggested that dose adjustment of imipramine may not be necessary.(7) A pharmacokinetic study found that carbamazepine 400 mg per daily for 4 weeks decreased plasma concentrations of mianserin by 34-45%. A doubling of the mianserin dose was proposed when coadministered with carbamazepine.(5) |
CARBAMAZEPINE, CARBAMAZEPINE ER, CARBATROL, EPITOL, EQUETRO, TEGRETOL, TEGRETOL XR |
The following contraindication information is available for TRIMIPRAMINE MALEATE (trimipramine maleate):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 2 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| 30 day risk period post-myocardial infarction |
| Serotonin syndrome |
There are 17 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Alcohol use disorder |
| Angle-closure glaucoma |
| Benign prostatic hyperplasia |
| Bipolar disorder |
| Cardiac arrhythmia |
| Cerebrovascular accident |
| Congenital long QT syndrome |
| Coronary artery disease |
| CYp2d6 intermediate metabolizer (activity score 1, no *10 allele present) |
| CYp2d6 poor metabolizer |
| Hyperthyroidism |
| Prolonged QT interval |
| Risk of angle-closure glaucoma due to narrow angle of anterior chamber of eye |
| Schizophrenia |
| Seizure disorder |
| Suicidal ideation |
| Urinary retention |
There are 5 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Disease of liver |
| Electroconvulsive therapy |
| Kidney disease with reduction in glomerular filtration rate (GFr) |
| Neutropenic disorder |
| Thrombocytopenic disorder |
The following adverse reaction information is available for TRIMIPRAMINE MALEATE (trimipramine maleate):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 29 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Abnormal sexual function Bradycardia Cardiac arrhythmia Erectile dysfunction Hypotension Parkinsonism Tremor |
| Rare/Very Rare |
|---|
|
Abnormal ECG Abnormal hepatic function tests Accidental fall Acute myocardial infarction Agranulocytosis Angioedema Blood dyscrasias Cerebrovascular accident Drug-induced psychosis Eosinophilia Heart block Hyperbilirubinemia Purpura Secondary angle-closure glaucoma Seizure disorder Serotonin syndrome SIADH syndrome Skin photosensitivity Suicidal ideation Tinnitus Ventricular fibrillation Ventricular tachycardia |
There are 51 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Accommodation disorder Anticholinergic toxicity Dizziness Drowsy Dysgeusia Headache disorder Increased appetite Palpitations Weight gain Xerostomia |
Acute cognitive impairment Blurred vision Constipation Diarrhea Dysuria Hallucinations Heartburn Hyperhidrosis Insomnia Libido changes Nervousness Upper respiratory infection Vomiting |
| Rare/Very Rare |
|---|
|
Aggressive behavior Agitation Akathisia Allergic dermatitis Alopecia Anorexia Delusional disorder Facial edema Galactorrhea not associated with childbirth Gynecomastia Hostility Hyperglycemia Hypertension Hypoglycemic disorder Hypomania Impulse control disorder Irritability Manic disorder Mydriasis Nausea Nightmares Panic disorder Paresthesia Pruritus of skin Skin rash Symptoms of anxiety Tachycardia Testicular swelling |
The following precautions are available for TRIMIPRAMINE MALEATE (trimipramine maleate):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for TRIMIPRAMINE MALEATE (trimipramine maleate):
WARNING: Antidepressant medications are used to treat a variety of conditions, including depression and other mental/mood disorders. These medications can help prevent suicidal thoughts/attempts and provide other important benefits. However, studies have shown that a small number of people (especially people younger than 25) who take antidepressants for any condition may experience worsening depression, other mental/mood symptoms, or suicidal thoughts/attempts.
It is very important to talk with the doctor about the risks and benefits of antidepressant medication (especially for people younger than 25), even if treatment is not for a mental/mood condition. Tell the doctor right away if you notice worsening depression/other psychiatric conditions, unusual behavior changes (including possible suicidal thoughts/attempts), or other mental/mood changes (including new/worsening anxiety, panic attacks, trouble sleeping, irritability, hostile/angry feelings, impulsive actions, severe restlessness, very rapid speech). Be especially watchful for these symptoms when a new antidepressant is started or when the dose is changed.
WARNING: Antidepressant medications are used to treat a variety of conditions, including depression and other mental/mood disorders. These medications can help prevent suicidal thoughts/attempts and provide other important benefits. However, studies have shown that a small number of people (especially people younger than 25) who take antidepressants for any condition may experience worsening depression, other mental/mood symptoms, or suicidal thoughts/attempts.
It is very important to talk with the doctor about the risks and benefits of antidepressant medication (especially for people younger than 25), even if treatment is not for a mental/mood condition. Tell the doctor right away if you notice worsening depression/other psychiatric conditions, unusual behavior changes (including possible suicidal thoughts/attempts), or other mental/mood changes (including new/worsening anxiety, panic attacks, trouble sleeping, irritability, hostile/angry feelings, impulsive actions, severe restlessness, very rapid speech). Be especially watchful for these symptoms when a new antidepressant is started or when the dose is changed.
The following icd codes are available for TRIMIPRAMINE MALEATE (trimipramine maleate)'s list of indications:
| Depression | |
| F32 | Depressive episode |
| F32.0 | Major depressive disorder, single episode, mild |
| F32.1 | Major depressive disorder, single episode, moderate |
| F32.2 | Major depressive disorder, single episode, severe without psychotic features |
| F32.3 | Major depressive disorder, single episode, severe with psychotic features |
| F32.4 | Major depressive disorder, single episode, in partial remission |
| F32.5 | Major depressive disorder, single episode, in full remission |
| F32.8 | Other depressive episodes |
| F32.89 | Other specified depressive episodes |
| F32.9 | Major depressive disorder, single episode, unspecified |
| F32.A | Depression, unspecified |
| F33 | Major depressive disorder, recurrent |
| F33.0 | Major depressive disorder, recurrent, mild |
| F33.1 | Major depressive disorder, recurrent, moderate |
| F33.2 | Major depressive disorder, recurrent severe without psychotic features |
| F33.3 | Major depressive disorder, recurrent, severe with psychotic symptoms |
| F33.4 | Major depressive disorder, recurrent, in remission |
| F33.40 | Major depressive disorder, recurrent, in remission, unspecified |
| F33.41 | Major depressive disorder, recurrent, in partial remission |
| F33.42 | Major depressive disorder, recurrent, in full remission |
| F33.8 | Other recurrent depressive disorders |
| F33.9 | Major depressive disorder, recurrent, unspecified |
| F34.1 | Dysthymic disorder |
Formulary Reference Tool